Impact of Intraoperative Hemodynamic Instability on Outcomes in Cardiac Surgery

Impact of Intraoperative Hemodynamic Instability on Postoperative Major Adverse Events in Cardiac Surgery Patients: A Prospective Cohort Study

Intraoperative hemodynamic instability (IOHI) is a common occurrence during cardiac surgery and is associated with organ hypoperfusion. However, the specific impact of IOHI on composite adverse outcomes remains unclear. This prospective cohort study aims to evaluate the association between intraoperative hemodynamic instability (defined as MAP < 65 mmHg or vasopressor requirement) and major postoperative complications (Delirium, Acute Kidney Injury, Stroke, or Mortality) in adult patients undergoing elective cardiac surgery with cardiopulmonary bypass.

Study Overview

Detailed Description

Hemodynamic instability during cardiac surgery is a critical factor influencing postoperative recovery. While transient hypotension is common, prolonged instability may lead to end-organ damage due to hypoperfusion. This prospective observational study will be conducted at the University of Health Sciences Gazi Yasargil Training and Research Hospital.

Patients scheduled for elective cardiac surgery (Coronary Artery Bypass Grafting, Valve replacement/repair, or combined procedures) utilizing cardiopulmonary bypass will be enrolled. Intraoperative hemodynamic data, including Mean Arterial Pressure (MAP), heart rate, and vasoactive medication requirements, will be recorded.

Patients will be categorized into two groups based on intraoperative stability:

  1. Hemodynamic Instability Group: Patients experiencing MAP < 65 mmHg for more than 5 minutes continuously or requiring significant vasopressor/inotropic support to maintain target pressure.
  2. Stable Group: Patients maintaining hemodynamic stability without significant hypotensive episodes.

The primary endpoint is a composite of major adverse events within 30 days, including Postoperative Delirium (assessed via CAM-ICU), Acute Kidney Injury (KDIGO criteria), Stroke, and All-cause Mortality. Secondary endpoints include the duration of mechanical ventilation and length of ICU/hospital stay. The study aims to provide evidence-based thresholds for intraoperative blood pressure management to improve patient outcomes.

Study Type

Observational

Enrollment (Actual)

351

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Diyarbakır
      • Diyarbakır, Diyarbakır, Turkey (Türkiye), 21070
        • Gazi Yaşargil Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients undergoing elective cardiac surgery with cardiopulmonary bypass at a tertiary care university hospital.

Description

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Scheduled for elective cardiac surgery (CABG, Valve replacement/repair, or combined procedures).
  • Surgery performed under cardiopulmonary bypass (CPB).
  • Preoperative sinus rhythm.
  • Signed informed consent form.

Exclusion Criteria:

  • Emergency or salvage surgery.
  • Off-pump coronary artery bypass grafting.
  • Preoperative mechanical circulatory support (IABP, ECMO) requirement.
  • Pre-existing chronic renal failure requiring dialysis (HD/PD).
  • Pre-existing cognitive impairment, dementia, or history of psychiatric disorders affecting cooperation.
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Hemodynamic Instability Group

Patients who exhibit intraoperative hemodynamic instability, defined as Mean Arterial Pressure (MAP) < 65 mmHg for >5 minutes continuously, or requiring vasopressor/inotropic support to maintain MAP.

Hemodynamically Stable Group

Patients who maintain intraoperative hemodynamic stability without significant hypotension episodes (MAP > 65 mmHg) or vasopressor requirement beyond baseline anesthesia induction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Composite Adverse Events
Time Frame: Up to 30 days post-operation

A composite endpoint defined as the occurrence of any of the following within 30 days post-surgery: Postoperative Delirium (assessed by CAM-ICU), Acute Kidney Injury (KDIGO criteria stage 1 or higher), Stroke (new neurological deficit confirmed by imaging), or All-cause Mortality.

Up to 30 days post-operation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of Mechanical Ventilation
Time Frame: Up to 30 days

Time from ICU admission to successful extubation (in hours).

Up to 30 days
Length of Hospital Stay
Time Frame: Up to 30 days

Total duration of hospital stay from surgery to discharge (in days)

Up to 30 days
Length of Intensive Care Unit (ICU) Stay
Time Frame: Up to 30 days

Time from admission to the Intensive Care Unit immediately after surgery until discharge to the ward (in days).

Up to 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 26, 2025

Primary Completion (Actual)

August 20, 2026

Study Completion (Actual)

September 20, 2026

Study Registration Dates

First Submitted

December 23, 2025

First Submitted That Met QC Criteria

December 23, 2025

First Posted (Actual)

January 7, 2026

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

October 2, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe